Aspirin News and Research

RSS

Aspirin also known as acetylsalicylic acid is a salicylate drug, often used as an analgesic to relieve minor aches and pains, as an antipyretic to reduce fever, and as an anti-inflammatory medication. Aspirin also has an antiplatelet, or "anti-clotting", effect and is used in long-term, low doses to prevent heart attacks, strokes and blood clot formation in people at high risk for developing blood clots. It has also been established that low doses of aspirin may be given immediately after a heart attack to reduce the risk of another heart attack or of the death of cardiac tissue.

Angioplasty no better than drugs for heart attack victims who delay treatment

In what will come as a surprise to many doctors, researchers in the United States how found that contrary to current belief, heart attack survivors with mild or no symptoms who wait three days or more to seek medical help, will achieve little benefit from the procedures used to open clogged arteries.

15 Nov 2006

Lifestyle decisions that may stave off onset of cancer

Personal choices, such as smoking and consumption of fatty foods, have long been linked to increased cancer risk. During recent years, scientists have been seeking to isolate a variety of lifestyle decisions that may stave off the onset of cancer or even reduce tumor formation in their early stages.

14 Nov 2006

Food can have an impact in preventing cancer

With cancer, researchers don't believe "you are what you eat"; that disease is always a direct result of what is, or what isn't, on your dinner plate.

14 Nov 2006

Link between common lifestyle factors, immune system and cancer

The immune system is fickle, and easily influenced by more than just viruses and bacteria. It can be swayed by the seemingly unexpected, such as by what we eat, for example, and affected by surprising sources.

13 Nov 2006

ODC genetic variation impacts aspirin's effectiveness in preventing colon cancer

Dartmouth researchers are among a team of doctors that have learned more about how people may or may not benefit from taking aspirin in the effort to curb colon cancer.

24 Oct 2006

Risks of gastrointestinal ulcers linked to aspirin use might outweigh its benefits for the heart in certain patients

Doctors should consider whether patients are at high risk of stomach ulcers before prescribing aspirin treatment.

20 Sep 2006

Researchers create roadmap to integrin activation

Calling it an important technical advance in the study of the complex receptors and pathways of the body's cellular system, researchers at the University of California, San Diego (UCSD) School of Medicine have reconstructed the signaling pathways that impact activation of a receptor that is critical to the control of bleeding and to the thrombosis that occurs in heart attacks and strokes.

18 Sep 2006

Messy nappies may be sign of severe intestinal infection

Anyone who's ever cared for an infant or young child knows what it's like to change the occasional smelly, messy diaper.

5 Sep 2006

Aspirin resistance: Fact or fable?

Coronary heart disease is the single leading cause of death in the Western world. Aspirin is a fundamental part of the prevention and treatment of coronary heart disease and is used by millions of patients worldwide.

5 Sep 2006

Simple bedside test may identify heart attack risk

The reason behind why patients who are on aspirin still have heart attacks is an important topic in cardiovascular disease.

5 Sep 2006

How effective is continued Plavix therapy in patients undergoing a repeat stent procedure?

Clopidogrel (Plavix) is used worldwide in millions of patients after placement of coronary artery stents. Sales of the drug exceed 5 billion US dollars.

5 Sep 2006

Aspirin may improve men's urinary health and prevent enlarged prostate

Researchers suggest that taking nonsteroidal anti-inflammatory drugs (NSAIDs) such as aspirin or ibuprofen may improve men's urinary health.

31 Aug 2006

VIOXX reduces risk of colorectal polyps

A researcher from Dartmouth reports the results of a clinical trial that shows that the cyclooxygenase-2 (COX-2) inhibitor rofecoxib (VIOXX.) reduces the risk of colorectal adenomas, or polyps.

30 Aug 2006

Celebrex shown to reduce incidence of potentially pre-malignant colorectal polyps

An international team of scientists reports that a single 400-milligram daily dose of celecoxib, commonly called Celebrex. and manufactured by Pfizer, significantly reduced recurrence of adenomas, or pre-malignant colon tumors - within three years of previous adenoma removal.

30 Aug 2006